The intent of the FY22 PRARP TRA is to support translational research that will accelerate the movement of promising products and knowledge in AD/ADRD research into clinical applications, including healthcare products and interventions, technologies, behavioral modalities, social modalities, and/or clinical practice guidelines. This mechanism supports both preclinical-to-clinical translational research (e.g., studies of interventions and medical devices in preclinical systems) and clinical research-to-clinical care translation (e.g., comparative effectiveness, implementation science, healthcare services research). Observations that support a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s first-hand knowledge of patients and anecdotal data. Inclusion of preliminary data is required. Use of animal models, if applicable, must be fully justified for relevance to human health. Clinical research applications are required to include a community collaboration research element.
Deadlines:
To address the intent of the award mechanism, applications submitted to this program announcement must address at least one of the FY22 PRARP TRA Focus Areas listed below. Selection of the appropriate Focus Area is the responsibility of the applicant.
1. Individual, caregiver, and family support: Clinical research focused on long-term care, quality of life, psychosocial wellness and support, and community and home resources supporting aging-in-place and community living for individuals living with dementia, their families, and care partners. For this Focus Area, “family” is broadly defined as the family of choice and/or the family of origin. Study population diversity is strongly encouraged. Applications including animal studies are not allowed for this Focus Area.
2. Diagnostic, environmental, and prognostic factors: Research to better detect, diagnose, support treatment decisions, and predict long-term outcomes and risk factors associated with AD/ADRD following military service and/or TBI. Research of interest may include, but is not limited to, identification and validation of biomarkers for diagnosis and prognosis of AD and ADRD, including, but not limited to, fluid, tissue, and imaging biomarkers, psychosocialindicators, development and validation of devices/technologies, or a combination thereof. In addition, research could address the contribution and identification of risk and resiliency factors for development of AD/ADRD during and after military service, which may include, but are not limited, to life history, genetic, physiological, and psychosocial factors. Epidemiological studies examining TBI and/or military-service-related factors and AD/ADRD development are also included under this Focus Area.
3. Foundational science to improve understanding of the mechanisms, etiology, comorbidities, therapeutics/treatments for AD/ADRD after TBI.
Independent investigators at all academic levels (or equivalent) may be named by the organization as the Principal Investigator (PI) on the application.
The anticipated total (direct plus indirect) costs budgeted for the entire period of performance for an FY22 PRARP Translational Research Award will not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
